Fosamax and Osteonecrosis of the Jaw: What Studies Show About Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure Concerns

The legacy domain of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic interventions. Within this context, broad awareness of medication side effects and disease risks has been cultivated through accessible, structured content. For instance, the relationship between bisphosphonate therapies and rare adverse events has been a topic of general interest, often framed in terms of patient education and clinical overviews. Transitioning from this broad health context to a more focused occupational exposure concern requires a shift in perspective. While the general public may encounter information about medications like Fosamax and its potential association with osteonecrosis of the jaw, the risk profile changes significantly when considering workplace environments. In mass production settings, workers may face repeated, low-level exposure to pharmaceutical compounds or their precursors during manufacturing, packaging, or quality control processes. This occupational exposure introduces variables—such as cumulative dose, inhalation or dermal contact, and lack of patient-level monitoring—that are distinct from prescribed therapeutic use. Thus, the bridge from general health information to occupational concern lies in recognizing that the same compound, when encountered in a production context, presents a different risk calculus. The focus shifts from patient outcomes to worker safety protocols, exposure limits, and industrial hygiene practices. This pivot sets the stage for examining how mass production environments must adapt their hazard communication and monitoring strategies to address potential risks that are not typically covered in general health literature.

Fosamax: Mechanism of Action and Recognized Adverse Effects

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves symptoms that may develop from one day to several months after starting the drug, and discontinuation is recommended if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, though a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Factors and Mechanistic Pathways for ONJ

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates, and for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ are supported by multiscale characterization of jawbone, which provides comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights that the jawbone has unique structural and cellular properties that may make it particularly susceptible to the effects of bisphosphonates, potentially contributing to ONJ development.

Epidemiological Evidence: Exposure Duration and Risk

Regarding the timeline between exposure and documented harm, a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study underscores that while the absolute risk is low, the relative risk increases with longer exposure duration.

Causation Considerations and Adequacy of Warnings

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax use and ONJ onset, as well as the presence of other risk factors. The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and that discontinuation may reduce risk for those requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled studies, symptom rates were similar between Fosamax and placebo groups, suggesting that ONJ may not be exclusively attributable to the drug in all cases (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a specific section on osteonecrosis of the jaw under warnings and precautions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label describes risk factors, the potential for increased risk with longer exposure, and the recommendation to consider discontinuation before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide healthcare providers and patients with information to assess and manage the risk. In summary, evidence indicates that Fosamax use is associated with an increased risk of ONJ, particularly with longer treatment duration and in the presence of additional risk factors such as invasive dental procedures. The absolute risk remains low, but the relative risk increases substantially over time. Warnings in the prescribing information aim to inform clinical decision-making, though the causal link in individual cases may be influenced by multiple factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. Fosamax and other bisphosphonates have been linked to an increased risk of ONJ, especially with longer treatment duration and additional risk factors such as invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk increases with longer exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does the risk of ONJ change with duration of Fosamax use?

A cohort study found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use. Absolute risks remained low, about 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Are there adequate warnings about ONJ in Fosamax prescribing information?

Yes, the prescribing information includes a specific section on osteonecrosis of the jaw under warnings and precautions, describing risk factors, the potential for increased risk with longer exposure, and recommendations to consider discontinuation before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.